Safety of short-term valacyclovir as an anti-sickling agent in sickle-cell anemia.

To assess safety and tolerability, we administered valacyclovir, an oral anti-viral medication that inhibits erythrocyte sickling in vitro, to 14 subjects with sickle-cell anemia for 1 week at a standard dose of 1,000 mg every 8 hr. No clinically significant adverse effects occurred. In 11 subjects in steady state, the mean hemoglobin concentration was almost constant while the absolute reticulocyte count decreased in eight (P = 0.1) and the overall mean fell slightly although not significantly (10%, P = 0.2). These results suggest that valacyclovir is safe and well tolerated in patients with sickle-cell anemia and that a longer duration of therapy merits investigation.

Immunochemical recognition of A2E, a pigment in the lipofuscin of retinal pigment epithelial cells.

The autofluorescent lipofuscin pigment A2E accumulates in retinal pigment epithelial cells with age and is particularly abundant in some retinal disorders. To generate a polyclonal antibody that recognizes this pyridinium bisretinoid molecule, we immunized rabbits with bovine serum albumin (BSA) conjugates in which the protein was linked to the A2E molecule via its pyridinium ethanolamine moiety. Analysis by matrix-assisted laser desorption ionization/time of flight mass spectrometry (MALDI-TOF MS) of the A2E-BSA conjugate indicated the presence of five intact A2E molecules covalently linked to BSA, thus deeming it a suitable antigen for immunization. By immunocytochemical staining, the rabbit polyclonal antibody recognized A2E that had accumulated in cultured cells, whereas dot-blot analysis revealed binding to both A2E and A2E-rabbit serum albumin (A2E-RSA) conjugate but no cross-reactivity with various retinoids. Preimmune serum was nonreactive. In fluorescence spectroscopy studies, antibody-A2E binding was evidenced by a fluorescence increase and by a blue-shift in the emission maximum consistent with a change in A2E milieu upon antibody binding. The changes in fluorescence emission upon antibody binding could reflect several processes including restrictions on trans-cis isomerization and intersystem crossing of photo-excited A2E.

Cell cycle inhibition by an anti-cyclin D1 antibodychemically modified for intracellular delivery.

Antibodies, especially monoclonal antibodies, are highly specific for their target antigens and have found extensive clinical application in the treatment of infectious diseases and neoplasia. However, they have a major shortcoming which, if overcome, would greatly expand their utility: an inability to penetrate the outer membrane of cells and act on intracellular targets. We demonstrated previously that this deficiency could be overcome by covalent linkage of an oligoarginine sequence to the conserved carbohydrate moiety present in the CH2 region of immunoglobulins. Immune specificity was maintained but no attempt was made to test for biological activity related to specificity. Here, we report that a polyarginated monoclonal anti-cyclin D1 enters cells and inhibits cell cycle progression. We demonstrate this with NIH 3T3 cells and with two tumor cell lines, HT29 and SW480. As many tumors overexpress cyclin D1, an intracellular anti-cyclin D1, properly targeted, has the potential to be a novel broad range inhibitor of tumor cell multiplication. Moreover, success with intracellular anti-cyclin D1 suggests that polyarginated antibodies, in general, could be a new, widely applicable experimental tool to investigate and influence intracellular processes, whether native to cells or introduced into cells by outside entities such as viruses.

A biologically effective fullerene (C60) derivative with superoxide dismutase mimetic properties.

Superoxide, a potentially toxic by-product of cellular metabolism, may contribute to tissue injury in many types of human disease. Here we show that a tris-malonic acid derivative of the fullerene C60 molecule (C3) is capable of removing the biologically important superoxide radical with a rate constant (k(C3)) of 2 x 10(6) mol(-1) s(-1), approximately 100-fold slower than the superoxide dismutases (SOD), a family of enzymes responsible for endogenous dismutation of superoxide. This rate constant is within the range of values reported for several manganese-containing SOD mimetic compounds. The reaction between C3 and superoxide was not via stoichiometric "scavenging," as expected, but through catalytic dismutation of superoxide, indicated by lack of structural modifications to C3, regeneration of oxygen, production of hydrogen peroxide, and absence of EPR-active (paramagnetic) products, all consistent with a catalytic mechanism. A model is proposed in which electron-deficient regions on the C60 sphere work in concert with malonyl groups attached to C3 to electrostatically guide and stabilize superoxide, promoting dismutation. We also found that C3 treatment of Sod2(-/-) mice, which lack expression of mitochondrial manganese superoxide dismutase (MnSOD), increased their life span by 300%. These data, coupled with evidence that C3 localizes to mitochondria, suggest that C3 functionally replaces MnSOD, acting as a biologically effective SOD mimetic.

Inhibition of sickling in vitro by three purine-based antiviral agents: an approach to the treatment of sickle cell disease.

As a result of an in vitro screening effort the antiviral agent acyclovir was found to inhibit aggregation of hemoglobin S and the sickling of erythrocytes from individuals with sickle cell disease. Sickling of the erythrocytes was significantly inhibited at 200 microg/ml under essentially anaerobic conditions, considerably more hypoxic than the conditions in which sickling occurs in sickle cell patients. The structurally related guanine-based antiviral agents ganciclovir, valacyclovir, and penciclovir were also tested. Valacyclovir and ganciclovir showed comparable anti-sickling activity at concentrations similar to that of acyclovir. An examination of the shared structural characteristics of the four guanine derivatives linked anti-sickling activity to the presence of an oxygen atom alpha to the N9 of the guanine moiety. These findings suggest a new approach in the search for new agents for the treatment of patients with sickle cell disease.

Intracellular delivery of monoclonal antibodies.

With some exceptions, antibodies do not have the ability to penetrate cell membranes and act intracellularly. Their usefulness in research and medicine would be considerably enhanced if they had the intrinsic ability to act on intracellular targets. We report here that covalently linking poly-L-arginine (average molecular weight 10750, ca. 68 residues) to the oligosaccharide moiety of the CH2 region of an immunoglobulin makes possible penetration into the cytoplasm and, and in some cases into the nucleus of cells. We demonstrate this with five antibodies and seven cell lines. Retention of specificity is demonstrated by ELISA with an anti-HIV Gag antibody and intracellularly with a monoclonal anti-tubulin antibody. As the antibodies are covalently modified, they have the potential to be used in intact animals.

Cellular localisation of a water-soluble fullerene derivative.

Fullerenes are a new class of compounds with potential uses in biology and medicine and many insights were made in the knowledge of their interaction with various biological systems. However, their interaction with organised living systems as well as the site of their potential action remains unclear. In this work, we have demonstrated that a fullerene derivative could cross the external cellular membrane and it localises preferentially to the mitochondria. We propose that our finding supports the potential use of fullerenes as drug delivery agents as their structure mimics that of clathrin known to mediate endocytosis.